Fludeoxyglucose F-18 and Fluorine F18 FDHT Positon Emission Tomography in Treating Patients with Progressive Prostate Cancer

Inclusion Criteria

• Patients with histologically confirmed prostate cancer
• Progressive disease manifest by either; * Imaging modalities: ** New osseous lesions on bone imaging (bone scintigraphy or sodium fluoride [NaF] PET scan) and/or ** An increase in measurable soft tissue disease, or the appearance of new sites of disease OR * A minimum of three rising prostate-specific antigen (PSA) values from a baseline that are obtained 1 week or more apart, or 2 or more weeks apart * PSA changes: ** Androgen-independent, minimum number (No.) of determinations 3, interval >= 1 week, percentage increase over 25% ** Androgen-independent, minimum No. of determinations 2, interval >= 2 week, percentage increase over 25%
• Visible lesions by either CT, bone imaging, or MRI consistent with disease
• Informed consent

Exclusion Criteria

• Previous anaphylactic reaction to either FDHT or FDG
• Bilirubin > 1.5 x upper limit of normal (ULN)
• Aspartate aminotransferase (AST)/ alanine aminotransferase (ALT) > 2.5 x ULN
• Albumin < 2 g/dl
• Gamma-Glutamyl Transpeptidase (GGT) > 2.5 x ULN IF alkaline phosphatase > 2.5 x ULN
• Creatinine > 1.5 x ULN or creatinine clearance < 60 mL/min